Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

NCT06860386 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

75

Enrollment

OTHER

Sponsor class

Stopped Funding unavailable

Conditions

Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Axitinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute